CogState releases details of UBC agreement
Tuesday, 29 July, 2008
Melbourne's CogState [ASX: CGS] has released the terms of its planned partnership with US pharmaceutical services company United BioSource Corporation [UBC], announced last week.
Under the arrangement, CogState and UBC will join forces to provide a comprehensive cognitive testing solution for use in clinical trials.
CogState markets six computerised diagnostic products to test cognitive function. It also has a therapeutic division with two compounds in early develop for Alzheimer's and Parkinson's diseases.
Under the agreement, UBC will buy a 15 per cent share in CogState, at a cost of around $800,000. UBC will also underwrite CogState's share rights issue.
Both companies will remain separate entities. In a statement to the stock exchange, CogState stressed that the arrangement will not necessitate any management changes or job losses.
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
TGA approves therapy for paediatric growth hormone deficiency
The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...
